{"nctId":"NCT00465985","briefTitle":"Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome","startDateStruct":{"date":"2007-04"},"conditions":["Muckle Wells Syndrome"],"count":35,"armGroups":[{"label":"Part I, Part II-arm1, & Part III","type":"EXPERIMENTAL","interventionNames":["Drug: ACZ885"]},{"label":"Part II - arm 2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ACZ885","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Molecular diagnosis of NALP3 mutations and clinical picture resembling Muckle-Wells Syndrome.\n* Muckle-Wells Syndrome patients who participated in the CACZ885A2102 study, will have the option to participate in this study upon disease flare\n* Muckle-Wells Syndrome patients requiring medical intervention either untreated or treated (i.e. under ACZ885, anakinra, or any other investigational IL-1 blocking therapy).\n\nExclusion Criteria:\n\n* History of being immunocompromised, including a positive HIV at screening test result.\n* No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.\n* History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial.\n* History of recurrent and/or evidence of active bacterial, fungal, or viral infections.\n* Positive tuberculin skin test at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit, according to national guidelines.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part)","description":"Determined by the Physician's global assessment of autoinflammatory disease activity, assessment of skin disease and inflammation markers. Data expressed as a percent of participants who had experienced a flare by the end of Part II.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Response in Part I (After 8 Weeks)","description":"Treatment response was based on Physician's global assessment(PGA) of autoinflammatory disease activity, assessment of skin disease(SD) and serum values of C-reactive protein(CRP) and/or serum amyloid A(SAA). Complete Response (CR):PGA and SD ≤ minimal and normal CRP and/or SAA. Partial Response (PR): a reduction of CRP and/or SAA from baseline (BL) by \\>30% but not reaching normal values and PGA improvement from BL by at least one category. Disease flare: a CRP and/or SAA \\> 30 mg/L and either PGA \\> minimal or PGA = minimal and SD \\> minimal. Non-responders = no PR by Day 8 or no CR by Day 15.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":"25.200"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part)","description":"A 5-point scale was used for the Physician's global assessment on autoinflammatory disease activity (absent, minimal, mild, moderate and severe) and for the assessment of the following items:\n\n* skin disease (urticarial skin rash)\n* arthralgia\n* myalgia\n* headache/migraine\n* conjunctivitis\n* fatigue/malaise\n* other symptoms related to autoinflammatory syndrome\n* other symptoms not related to autoinflammatory syndrome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"3.086"},{"groupId":"OG001","value":"19.93","spread":"24.175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"8.604"},{"groupId":"OG001","value":"71.09","spread":"136.637"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (CLD (L/d))","description":"Assessed serum clearance of ACZ885.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.177","spread":"0.085"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced a Disease Flare in Part II","description":"Disease flare is determined by the Physician's global assessment of autoinflammatory disease activity, assessment of skin disease and inflammation markers. Disease Flare = the C-reactive protein and/or serum amyloid A (SAA) \\> 30 mg/L and either a PGA \\> minimal, or PGA equal to minimal and \\> minimal SD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part I.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.047","spread":"17.6609"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part II.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.943","spread":"10.3698"},{"groupId":"OG001","value":"0.596","spread":"0.7289"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part III.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.018","spread":"16.5193"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Nasopharyngitis","Diarrhoea","Rhinitis","Influenza","Nausea"]}}}